Company Information


Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that leverage the body’s immune system to fight cancer and infectious diseases. Agenus has established a highly integrated approach to validate targets of interest, identify therapeutically relevant biomarkers, engineer highly differentiated therapies, and explore novel immunotherapy combinations. The company supports discovery and development efforts with wholly-owned, advanced clinical and manufacturing capabilities and pursues strategic partnerships as means of accelerating development timelines. The company currently has active collaborations with several leaders in the oncology field, including Bristol Myers, Merck, Gilead and Incyte. Through its subsidiaries, MiNK therapeutics and SaponiQx, Agenus is pursuing allogeneic cell therapies and vaccine adjuvants, respectively.

Press Releases
Aug 09, 2022
Botensilimab (Fc-enhanced CTLA-4)/balstilimab (PD-1) combination data presented at the 2022 ESMO World GI Congress demonstrated remarkable clinical activity in microsatellite stable colorectal cancer (MSS CRC) Agenus expects to present additional botensilimab expansion cohort data at upcoming
Aug 02, 2022
LEXINGTON, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will attend the BTIG Biotechnology Conference.

btn News

Events and Presentations

SEC Filings

Form Description Filing date View

Registration statement for face-amount certificate companies


Amended Registration statement for face-amount certificate companies


Data provided by Kaleidoscope.

btn SEC